合富中国：预计2025年全年扣非后净利润亏损2400万元至3500万元

Core Viewpoint - Company expects a net profit loss of 24 million to 35 million yuan for the full year of 2025 due to various challenges in the market and operational adjustments [1] Group 1: Performance Forecast - Company anticipates a net profit loss of 24 million to 35 million yuan for 2025 after deducting non-recurring items [1] - The decline in profit is attributed to changes in the macro environment and the impact of centralized procurement policies in the in-vitro diagnostics industry [2] Group 2: Reasons for Performance Changes - The competitive landscape is being reshaped, leading to decreased product procurement prices from hospital clients and fluctuations in order volumes, which pose challenges to sales revenue and gross profit levels [2] - Despite cost-saving measures, fixed expenditures cannot be reduced proportionally to income, and investments in talent optimization and capability upgrades have contributed to the expected losses [2] - The company is actively adjusting its business layout and development strategy, focusing on the technological iteration and innovation of its proprietary "ACME" products, increasing R&D investment, and expanding the market development team [2] Group 3: Financial Performance - For the first three quarters of 2025, the company's main revenue was 549 million yuan, a year-on-year decrease of 22.8% [3] - The net profit attributable to the parent company was -12.39 million yuan, a year-on-year decline of 146.65% [3] - The gross profit margin stood at 15.84%, with a debt ratio of 27.18% [3]